NBRVF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBRVF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nabriva Therapeutics's Revenue per Share for the three months ended in Jun. 2023 was $0.80.
During the past 12 months, Nabriva Therapeutics's average Revenue per Share Growth Rate was -34.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Nabriva Therapeutics was -20.10% per year. The lowest was -21.20% per year. And the median was -20.65% per year.
For the Biotechnology subindustry, Nabriva Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Nabriva Therapeutics (OTCPK:NBRVF) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Nabriva Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Hogan H Michael Iii | officer: Chief Executive Officer | C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355 |
David Maggio | officer: Chief Financial Officer | 15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248 |
Mark Corrigan | director | |
Broom Colin Md | officer: Chief Executive Officer | 119 FRINGETREE DRIVE, WEST CHESTER PA 19380 |
Stephen W Webster | director | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Daniel D Burgess | director | C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
Carrie L. Bourdow | officer: Director | C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Theodore R Schroeder | officer: Chief Executive Officer | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
J. Christopher Naftzger | officer: General Counsel and Corp Sec | 633 LOWTHER ROAD, LEWISBERRY PA 17339 |
Christine J. Guico-pabia | officer: Chief Medical Officer | C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034 |
Lisa Dalton | director | 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104 |
Daniel Dolan | officer: Chief Financial Officer | C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406 |
Francesco Maria Lavino | officer: Chief Commercial Officer | 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406 |
Robert Crotty | officer: General Counsel & Corp Sec. | 1301 2ND AVE, SEATTLE WA 98101 |
From GuruFocus
By Value_Insider Value_Insider • 11-28-2022
By Don Li2 Don Li2 • 11-11-2021
By PurpleRose PurpleRose • 07-20-2022
By GuruFocusNews GuruFocusNews • 01-18-2022
By GuruFocusNews GuruFocusNews • 06-12-2022
By GuruFocusNews GuruFocusNews • 03-01-2022
By Marketwired Marketwired • 10-15-2021
By Marketwired Marketwired • 10-01-2021
By GuruFocusNews GuruFocusNews • 12-21-2021
By Don Li2 Don Li2 • 11-05-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.